Molecular Cancer Therapeutics · 2013 · 121 citations · 31 references
Life SciencesMolecular BiologyOncologyCell SignalingMolecular OncologySignal TransductionAmino Acid MetabolismEnzyme InhibitionMetabolic ReprogrammingMetabolic Reprogramming In CancerTherapeutic ResistanceAnticancer Drug ResistanceArginine Deiminase SystemCellular Metabolic ReprogrammingMolecular Drug ResistancePhosphatidylinositol 3-Kinase Akt SignalingPi3k InhibitorsRate-limiting EnzymesTumor Resistance
Many malignant human tumors, including melanomas, are auxotrophic for arginine due to reduced expression of argininosuccinate synthetase-1 (ASS1), the rate-limiting enzyme for arginine biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which degrades extracellular arginine, resulting in arginine deprivation, has shown favorable results in clinical trials for treating arginine-auxotrophic tumors. Drug resistance is the major obstacle for effective ADI-PEG20 usage. To elucidate mechanisms of resistance, we established several ADI-PEG20-resistant (ADI(R)) variants from A2058 and SK-Mel-2 melanoma cells. Compared with the parental lines, these ADI(R) variants showed the following characteristics: (i) all ADI(R) cell lines showed elevated ASS1 expression, resulting from the constitutive binding of the transcription factor c-Myc on the ASS1 promoter, suggesting that elevated ASS1 is the major mechanism of resistance; (ii) the ADI(R) cell lines exhibited enhanced AKT signaling and were preferentially sensitive to PI3K/AKT inhibitors, but reduced mTOR signaling, and were preferentially resistant to mTOR inhibitor; (iii) these variants showed enhanced expression of glucose transporter-1 and lactate dehydrogenase-A, reduced expression of pyruvate dehydrogenase, and elevated sensitivity to the glycolytic inhibitors 2-deoxy-glucose and 3-bromopyruvate, consistent with the enhanced glycolytic pathway (the Warburg effect); (iv) the resistant cells showed higher glutamine dehydrogenase and glutaminase expression and were preferentially vulnerable to glutamine inhibitors. We showed that c-Myc, not elevated ASS1 expression, is involved in upregulation of many of these enzymes because knockdown of c-Myc reduced their expression, whereas overexpressed ASS1 by transfection reduced their expression. This study identified multiple targets for overcoming ADI-PEG resistance in cancer chemotherapy using recombinant arginine-degrading enzymes.
31
Ralph J. DeBerardinis, Anthony Mancuso, Evgueni Daikhin et al. · Proceedings of the National Academy of Sciences · 2007 · 2.6K citations · Full text
Genomic targets of the human c-Myc protein
Paula Fernández, Scott R. Frank, Luquan Wang et al. · Genes & Development · 2003 · 972 citations · Full text
Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells
Jihye Yun, Carlo Rago, Ian Cheong et al. · Science · 2009 · 909 citations · Full text
Medicine, Cancer Biology, Oncology +17